Nuvectis Pharma (NVCT) KOL Event summary

Introduction and agenda

• Discussion centered on the NXP900 Phase 1b program in advanced solid tumors, including combination with osimertinib in non-small cell lung cancer, with forward-looking statements on clinical progress and timelines.

• The agenda included a review of the mechanism of action, preclinical data, clinical program details, KOL presentations, and a Q&A session.

KOL background and credentials

• Dr. Asier Unciti-Broceta, co-inventor of NXP900, is a professor and director at the University of Edinburgh, specializing in medicinal chemistry and cancer drug development.

• Dr. Alexander Spira, Chief Scientific Officer at Next Oncology, is an experienced clinical oncologist and principal investigator in EGFR inhibitor development.

• Speakers also included Ron Bentsur (CEO) and Dr. Alexander Spira (Virginia Cancer Specialists, NEXT Oncology).

Market insights and analysis

• The addressable population for NXP900 in non-small cell lung cancer is estimated at 45,000 patients, representing a significant market opportunity.

• NSCLC treatment paradigms highlight significant unmet needs, especially in second line where survival outcomes with docetaxel remain poor.

• FLAURA2 and MARIPOSA studies show evolving standards in EGFR-mutated NSCLC, with persistent gaps post-progression.

• Oral regimens like NXP900 may offer advantages in tolerability and convenience over existing intravenous options.